Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Cromwell REIT Placement - Acquisition Was Announced Well Ahead and Placement Likely Expected

Cromwell European REIT (CERT SP) - Opportunity Knocks?

Cromwell EREIT IPO: Third Time Downsized, What's New?

Cromwell EREIT IPO: Downsized to Save the Day but Valuation Remains Unappealing

Cromwell European REIT: Decent Yield, Decent Size - But Where Is the Growth?

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Cromwell European REIT / Equity Capital Markets

<p>Cromwell REIT announced an EUR 100 million private placement this morning. The company is raising capital for the acquisition of six properties in Poland and France. In this insight, we will look at the transaction and the impact on key financial metrics. We will provide our thoughts on the deal and score the deal in our ECM framework. </p>

Cromwell REIT announced an EUR 100 million private placement this morning. The company is raising capital for the acquisition of six properties in Poland and France. In this insight, we will look at the transaction and the impact on key financial metrics. We will provide our thoughts on the deal and score the deal in our ECM framework. 

Cromwell REIT Placement: DPU Accretive at the Cost of Increasing EM Exposure